相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib
Gary M. Clark
MOLECULAR ONCOLOGY (2008)
Cigarette smoking and irinotecan treatment: Pharmacokinetic interaction and effects on neutropenia
Jessica M. van der Bol et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors
L. V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes
Jing Li et al.
CLINICAL CANCER RESEARCH (2007)
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Erminia Massarelli et al.
CLINICAL CANCER RESEARCH (2007)
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group study BR.21
Andrea Bezjak et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer
AS Tsao et al.
CANCER (2006)
Erlotinib: Optimizing therapy with predictors of response?
Susan Goodin
CLINICAL CANCER RESEARCH (2006)
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21
Gary M. Clark et al.
CLINICAL LUNG CANCER (2006)
Effects of smoking on the pharmacokinetics of erlotinib
M Hamilton et al.
CLINICAL CANCER RESEARCH (2006)
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen
JR Johnson et al.
CLINICAL CANCER RESEARCH (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Erlotinib in lung cancer - Molecular and clinical predictors of outcome
MS Tsao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung
LT Nordquist et al.
CHEST (2004)
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
M Hidalgo et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
